Logo

Protagen Raises $1.5M in Third Round of Financing

Jan 15, 2008
NEW YORK (GenomeWeb News) – Dortmund, Germany-based Protagen today said that it has raised €1 million ($1.5 million) in a third round of financing with private investors.
 
Protagen said it would use the funds to expand its protein biochips business. The firm said it has developed a unique protein biochip technology package, called UNIarray, for the discovery and validation of biomarkers.
 
It also is working on diagnostics for multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, and Alzheimer’s disease.
 
Investors in this round of financing included Munich-based MIG AG and Co KG Beteiligungsfonds 3, S-Venture Capital Dortmund, and Kreditanstalt für Wiederaufbau.
 
Protagen has raised a total of €5.3 million since 2004.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.